Nanobac Announces Researchers Describe Links Between Nanobacterial Infections, Dental Plaque, Periodontal Disease and Peripheral Arterial Vascular Disease

Business Wire,  Sept 19, 2003  

• E-mail
• Print
• Link

Business Editors/Health & Medical Writers

TAMPA, Fla.--(BUSINESS WIRE)--Sept. 19, 2003

In a letter to the editor of the American Heart Associaton's Circulation magazine, researchers from Nanobac Oy, a research group in Kuopio, Finland and subsidiary of Nanobac Pharmaceuticals, Inc. (OTCPK:NNBP), announced that their findings show an association between nanobacterial infection, dental plaque and periodontal disease.

Nanobac OY scientists, Neva Ciftcioglu, Ph.D. and E. Olavi Kajander, M.D., Ph.D., with David S. McKay, Ph.D. at NASA Johnson Space Center, Houston, Texas, described their findings in a letter in the August 26, 2003 issue. Their letter was in response to a study by Harvard public health epidemiologists, Hung, Willet, Merchant, et al published in an earlier issue of the magazine. The Harvard Study showed a relationship between periodontal disease and the development of peripheral arterial vascular disease. In response, the Harvard epidemiologists agreed that the association of nanobacterial infections, dental plaque, periodontal disease and peripheral arterial vascular disease is worthy of further study.

Nanobacteria, through infection of human tissues, have the unique ability to cause both calcification deposits and inflammation inside infected tissues. They have been shown in multiple, previously published studies to be present in dental plaque, periodontal plaque, coronary artery plaque, aortic plaque, kidney stones, gallstones and in other tissues.

Nanobac Pharmaceuticals, Inc. is the leader in nanobacterial infectious disease research and development, and owns the proprietary methods of detection and treatment of nanobacterial infections. The company's nanobacterial diagnostics and prescription nanobiotic(R) medications, demonstrated to safely and effectively treat nanobacterial infections in coronary artery heart disease and vascular disease, are available to qualified physicians.

Reprints of the article, "Association between Nanobacteria and Periodontal Disease", Circulation, Volume 108, No 8, August 26, 2003, e58-e59, may be obtained online from the American Heart Association at http://www.circulation.com.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida, U.S.A. For more information, please visit our website at: http://www.nanobaclabs.com.

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

COPYRIGHT 2003 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning